Weekly Epidemiological Record
100 YEARS OF THE WEEKLY EPIDEMIOLOGICAL RECORD
Volume 101 • Issue 45
Epidemiological Week 45 (2 November – 8 November 2026)

The Weekly Epidemiological Record (WER) was first issued in 1926 by the Health Office of the League of Nations. It was entrusted to the World Health Organization (WHO) when it was created in 1948 and has appeared every week since then.

It serves as an essential instrument for the rapid and accurate dissemination of epidemiological information on cases and outbreaks of diseases under the IHR and on other communicable diseases of public health importance, including emerging or re-emerging infections.

An electronic version of the WER is accessible every Friday and can be downloaded free of charge.

 

Inside this issue

WER_101_45
Latest issue
Vol. 101 • Issue 45
13 November 2026
Issue 44 6 November 2026 · pp. 322–343
PDF | HTML
Issue 43 30 October 2026 · pp. 319–321
PDF | HTML
Issue 42 23 October 2026 · pp. 314–318
PDF | HTML
Issue 41 16 October 2026 · pp. 302–313
PDF | HTML
Issue 40 9 October 2026 · pp. 284–301
PDF | HTML
Issue 39 2 October 2026 · pp. 252–283
PDF | HTML
Issue 38 25 September 2026 · pp. 221–251
PDF | HTML
Issues 36–3718 September 2026 · pp. 203–220
PDF|HTML
Issue 354 September 2026 · pp. 193–202
PDF|HTML
Issue 3428 August 2026 · pp. 187–192
PDF|HTML
Issue 33 21 August 2026· pp. 182–186
PDF | HTML
Issue 32 14 August 2026· pp. 166–181
PDF | HTML
Issue 31 7 August 2026· pp. 157–165
PDF | HTML
Issue 30 31 July 2026 · pp. 134–156
PDF | HTML
Issue 29 24 July 2026 · pp. 122–133
PDF | HTML
Issue 28 17 July 2026 · pp. 104–121
PDF | HTML
Issue 27 10 July 2026 · pp. 98–103
PDF | HTML
Issue 26 3 July 2026 · pp. 93–97
PDF | HTML
Issue 25 26 June 2026 · pp. 87–92
PDF | HTML
Volume 101 · 2026 ︿ Volume 101 · 2026 ﹀
Weekly Epidemiological Record archive
Archive
Previous editions
✉️
Receive weekly updates by email
Subscribe to the mailing list
WHO team Department of Alert, Response and Operations
Contact: WER
© WHO · Copyright

 

Highlighted signals and events

During epidemiological week 45 (2–8 November 2026), WHO Public Health Intelligence (PHI) teams conducted digital event-based surveillance (DEBS) to support the early detection and assessment of potential public health threats. During the reporting period, 565 268 raw signals were screened across multiple sources. Of these, 23 signals were categorized for further assessment, including 22 unique signals. A total of 16 signals were escalated for further action.

During the reporting week, two new events were registered in the Event Management System (EMS): an event not yet diagnosed in Brazil and seasonal influenza in Vanuatu. Three Disease Outbreak News (DON) reports were published. A summary of the signal assessment metrics, selected signals of potential public health events, published information products and newly registered EMS events is provided below.

Map of select newly reported public health events, 2–8 November 2026
Figure 1. Map of select newly reported public health events, 2–8 November 2026
CloseMap of select newly reported public health events, 2–8 November 2026
Figure 1. Map of select newly reported public health events, 2–8 November 2026
Signal assessment metrics
2–8 November 2026
Signals screened1Signals categorized2Unique signals3Signals escalated4
565 268232216

1 Signals screened: Total volume of raw signals reviewed from across multiple sources during the reporting period.

2 Signals categorized: Number of signals categorized for further detailed WHO assessment and actions during the reporting period.

3 Unique signals: Count of distinct signals after removing duplicate or repeated entries from different sources within the same epidemiological week.

4 Signals escalated: Subset of categorized signals that triggered escalation actions.

Selected new signals of potential public health events assessed5,6
2–8 November 2026
RegionHazard
Africa

Anthrax, unspecified

Cholera

Dengue

Diphtheria

Not yet diagnosed

Yellow fever

Americas

Influenza due to identified avian or animal influenza virus

Klebsiella pneumoniae

Natural disaster

Eastern MediterraneanDiphtheria
EuropeChikungunya virus disease
South-East AsiaNo publicly available signals identified
Western PacificInfluenza due to identified avian or animal influenza virus

5 The absence of listed signals indicates that no publicly available signals were identified during the reporting period and does not imply absence of signal activity overall.

6 Only new events registered during the defined period are included. Accordingly, changes to the disease/condition that occur after the data cut-off of 23:59 on 8 November 2026 will not be reflected in the description. The absence of events indicates that no publicly available newly reported events were identified during the reporting period and does not imply absence of event activity overall.

Show lessShow more

To the top ↑

Schistosomiasis and soil-transmitted helminthiases: progress report, 2025

Background

Schistosomiasis and soil-transmitted helminthiases (STH) are neglected tropical diseases (NTDs) that remain major public health problems in many countries, particularly where access to safe water, sanitation and hygiene is limited. Schistosomiasis is caused by parasitic worms of the Schistosoma genus, while STH are mainly caused by Ascaris lumbricoides, Trichuris trichiura, Strongyloides stercoralis, and hookworms (Ancylostoma duodenale and Necator americanus). These infections can lead to anaemia, malnutrition, impaired growth and development, and, in the case of schistosomiasis, severe organ damage and genital disease.

The populations at greatest risk include preschool-aged children (pre-SAC, 1–4 years of age), school-aged children (SAC, 5–14 years of age), women of reproductive age and, for schistosomiasis, adults living in endemic communities, due to their occupations in link with contaminated water. To reduce morbidity and interrupt transmission, WHO recommends an integrated approach combining preventive chemotherapy (PC) with praziquantel for schistosomiasis, albendazole or mebendazole for Ascaris lumbricoides, Trichuris trichiura and hookworms, and ivermectin for Strongyloides stercoralis, alongside improvements in water, sanitation and hygiene (WASH), health education, and complementary interventions such as snail control for schistosomiasis.

Considerable progress has been made in reducing the burden of schistosomiasis and STH. The estimated STH burden measured in disability-adjusted life years (DALYs) had decreased from 3 million in 2010 to 1.7 million in 20231. In addition, the published data showed a 69.6% reduction in a global age-standardized STH prevalence in 2020 compared to 1990 with 75.8%, 59.9% and 82.9% reduction of infections due to Ascaris lumbricoides, Trichuris trichiura and hookworms respectively2. For schistosomiasis, the reduction of DALYs was low, 2.3 million in 2010 to 2.1 million in 20231.

The NTD road map places increasing emphasis not only on maintaining effective PC, but also on measuring programme impact, adapting the frequency of interventions to the epidemiological situation and progressing towards elimination of schistosomiasis and STH as a public health problem.

Status of countries in PC coverage in 2025

Schistosomiasis was endemic in 79 countries in 2025. Transmission of Schistosoma haematobium was confirmed in Cabo Verde, a country which was not previously endemic4. In 2025, PC was required for schistosomiasis in 50 countries with 129 million SAC and 107.1 million adults in need of treatment. For STH, PC was required in 84 countries: 247.6 million pre-SAC and 609 million SAC corresponding to approximately 856.6 million children across the two principal target groups.

This report documents global and regional progress in PC coverage for schistosomiasis and STH in 2025 and the impact of control intervention as reported by ministries of health to WHO. An online PC data portal5 holds details on each endemic country, including data reported by non-governmental organizations after validation by countries. Details of the methods used to collect and analyse data have been published.6 Data from the country reports for 2025 that had not been received at the time of publication will be made available on the PC data portal.

Numbers of people treated for schistosomiasis and STH in 2025

Provision of PC for schistosomiasis and STH in 2025, globally and by WHO region, is summarized in Table 1. In 2025, PC was provided to 77.4 million people (65.1 million SAC and 12.3 million adults) for schistosomiasis in 38 countries, reaching 32.8% global coverage (50.5% for SAC and 11.5% for adults). In addition, 466 488 children less than 5 years of age were reported to receive PC for schistosomiasis in two countries – 159 854 children in the United Republic of Tanzania (Zanzibar) and 306 634 children in the Philippines – using the current praziquantel formulation. Among the children requiring PC for STH, approximately 94 million pre-SAC and 302.2 million SAC were treated. This corresponded to global coverage of 37.9% among pre-SAC and 49.6% among SAC, with an overall treatment coverage of 46.2%.

In the African region, 63.6 million SAC and 10.7 million adults received PC for schistosomiasis, reaching a regional coverage of 33.4% (51.7% for SAC and 10.7% for adults). For STH, 95.4 million children in need of treatment were covered by PC (39.1%) in 2025 (17.3% for pre-SAC and 49.4% for SAC). Only 11 and 27 countries out of 37 reported the treatment of pre-SAC and SAC respectively.

Table 1. Global and regional numbers of people treated with preventive chemotherapy (PC) for soil-transmitted helminthiases and schistosomiasis in 2025
WHO Region
AfricanThe AmericasSouth-East AsiaEuropeanEastern MediterraneanWestern PacificGlobal
Soil-transmitted helminthiases
Number of countries requiring PC37167361584
Number of countries with no data available0000022
Preschool-aged children
Number of countries reporting114302626
Number of preschool-aged children requiring PC78 695 4957 106 822111 011 7851 881 48616 269 52432 666 442247 631 554
Number of preschool-aged children requiring PC treateda13 644 3381 117 73853 578 40506 893 03318 722 52293 956 036
Coverage (%)17.315.748.3042.457.337.9
School-aged children
Number of countries reporting275413747
Number of school-aged children requiring PC165 438 03118 474 956303 503 4973 497 24935 869 42682 251 990609 035 149
Number of school-aged children requiring PC treateda81 789 4195 300 024139 851 27325 28315 683 58359 508 504302 158 086
Coverage (%)49.428.746.10.743.772.349.6
Total number of children
Total number of children requiring PC244 133 52625 581 778414 515 2825 378 73552 138 950114 918 432856 666 703
Total number of children requiring PC and treateda95 433 7576 417 762193 429 67825 28322 576 61678 231 026396 114 122
Coverage (%)39.125.146.70.543.368.146.2
Schistosomiasis
Number of countries requiring PC412003450
School-aged children
Number of countries reporting311002438
Number of school-aged children requiring PC123 057 715305 286004 282 4641 352 526128 997 991
Number of school-aged children requiring PC treated63 592 85056900649 568920 59165 163 578
Coverage (%)51.70.20015.268.150.5
Adults
Number of countries reporting191001425
Number of adults requiring PC99 628 3381 283 812003 787 4542 374 741107 074 345
Number of adults requiring PC treated10 676 3463 381008281 601 58912 282 144
Coverage (%)10.70.3000.0267.411.5
Total number of people
Total number of people requiring PC222 686 0531 589 098008 069 9183 727 267236 072 336
Total number of people requiring PC and treated74 269 1963 95000650 3962 522 18077 445 722
Coverage (%)33.40.3008.167.732.8

a Number treated in areas requiring PC is the number of children received PC for STH at least once in the reporting year in areas where baseline prevalence of infection is ≥20% or impact prevalence is ≥2%.

In the Americas, no PC for schistosomiasis was conducted in Venezuela (Bolivarian Republic of), while Brazil reported treatment of 569 SAC and 3381 adults. For STH, among the16 endemic countries, 11 had conducted PC at least once in the last five years and for 2025, only five countries reported PC for STH treating 6.4 million children representing 25.1% regional coverage (15.7% for pre-SAC and 28.7% for SAC). Four endemic countries (Bolivia [Plurinational State of], Dominica, Panama and Saint Vincent and the Grenadines) had not reported any treatment to WHO for the last 10 years.

In the Eastern Mediterranean region, among the three countries requiring PC for schistosomiasis, Somalia and Yemen reported treatments while Sudan has not implemented PC for schistosomiasis. Egypt, after tremendous long-term effort, has decreased the prevalence of schistosomiasis to a level where it could be considered as not requiring PC. The country is now implementing a test-and-treat strategy. For STH, four countries (Afghanistan, Pakistan, Somalia and the Syrian Arab Republic) out of six STH endemic countries reported treatment in 2025 with a total regional coverage of 43.3%.

In the European region, only one of the three countries endemic for STH, Kyrgyzstan, reported treatment of 25 283 SAC which represented 0.5% of the total children in need of PC in the region.

In the South-East Asia region, PC for STH was conducted in four out of the seven countries requiring mass treatment, reaching 193.4 million children with a regional coverage of 46.7%. Bangladesh, the highest-burden country for STH (more than 55 million children in need of PC) did not conduct mass drug administration (MDA) for STH in 2025, which corresponds to a decrease in regional coverage (65.7% in 2024). Bhutan and the Democratic People’s Republic of Korea did not report on PC treatment in 2025.

In the Western Pacific region, all four schistosomiasis endemic countries (Cambodia, Indonesia, Lao People’s Democratic Republic and the Philippines) submitted reports, with a total of 2.5 million people treated, representing 67.7% regional coverage. Among the 15 endemic countries on the region for STH, only seven reported treatment data, with a total of 78.2 million children treated (68.1%). Among the eight countries that did not report, four of them (Marshall Islands, Micronesia [Federated States of], Naoero, and Solomon Islands) had not reported any treatment data for the last 5 years.

In 2025, 17 of the 38 countries that implemented PC for schistosomiasis achieved ≥75% national coverage for SAC, and 14 of the 47 countries that implemented PC for STH reached the 75% coverage target for SAC.

Table 2 shows progress in countries that require PC for STH and schistosomiasis in 2025 in providing PC for SAC, the age group for which drugs are donated.

Table 2. Progress in implementation of preventive chemotherapy (PC) for school-aged children (SAC) against soil-transmitted helminthiases (STH) and schistosomiasis in 2025
Countries not implementing PC or not reporting for SAC in 2025Countries implementing PC for SAC in 2025 with <75% national coverageCountries implementing PC for SAC in 2025 with ≥75% national coverage
Soil-transmitted helminthiases
Afghanistana, Bangladesha, Bhutanb, Bolivia (Plurinational State of)b, Botswanaa, Brazila, Cabo Verdea, Comorosa, Democratic People's Republic of Koreab, Dominicab, Equatorial Guineaa, Eswatinia, Fijib, Gambiac, Guatemalab, Guyanab, Haitib, Hondurasb, Iraqa, Lesothoa, Malawia, Marshall Islandsb, Micronesia (Federated States of)b, Naoerob, Panamab, Papua New Guineaa, Perub, Saint Vincent and the Grenadinesb, Solomon Islandsb, South Africaa, Tajikistana, Tongab, Tuvalub, Uzbekistanb, Venezuela (Bolivarian Republic of)b, Yemena, ZambiaaAngola, Benin, Burundi, Cameroon, Central African Republic, Chad, Colombia, Congo, Democratic Republic of the Congo, Gabon, Guinea-Bissau, India, Kenya, Kiribati, Kyrgyzstan, Lao People's Democratic Republic, Liberia, Mozambique, Myanmar, Nepal, Nigeria, Paraguay, Philippines, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, Syrian Arab Republic, Togo, Uganda, United Republic of Tanzania, Vanuatu, ZimbabweCambodia, Côte d'Ivoire, Dominican Republic, El Salvador, Ethiopia, Guinea, Indonesia, Madagascar, Nicaragua, Pakistan, Rwanda, South Sudan, Timor-Leste, Viet Nam
373314
Schistosomiasis
Botswanaa, Equatorial Guineaa, Eritreaa, Eswatinia, Gabona, Gambiaa, Mozambiquea, Namibiaa, South Africaa, Sudana, Venezuela (Bolivarian Republic of)a, ZambiaaAngola, Benin, Brazil, Central African Republic, Ghana, Indonesia, Kenya, Liberia, Malawi, Niger, Nigeria, Philippines, Rwanda, Sao Tome and Principe, Sierra Leone, Somalia, South Sudan, United Republic of Tanzania, Togo, Uganda, YemenBurkina Faso, Burundi, Cambodia, Cameroon, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Ethiopia, Guinea, Guinea-Bissau, Lao People's Democratic Republic, Madagascar, Mali, Mauritania, Senegal, Zimbabwe
122117

a Countries did not implement PC for SAC in 2025 for the disease

b Countries have not reported on PC implementation in 2025

c Countries submitted report on PC implementation in 2025, which is under validation

Progress towards the 2030 NTD road map targets

The main goal of the programmes to control schistosomiasis and STH is to eliminate morbidity associated with these diseases in the target population by reducing the prevalence of moderate- and heavy-intensity infections and the overall prevalence of infection mainly by PC with praziquantel and either albendazole or mebendazole.

WHO recommends to endemic countries a collection of parasitological data after five years of PC with effective coverage (≥75%) to show the impact of the programme and revise their PC strategy according to the new epidemiological situation. For STH, in countries requiring PC in 2025, 472 implementation units (IU) suspended PC or are implementing events-based PC following the results of impact assessment surveys and most of them (439 IU) are in the African region. The road map target for STH and schistosomiasis is the elimination of both diseases as a public health problem, which is defined as a cumulative prevalence of moderate and heavy intensity infections of < 2% for STH and <1% for schistosomiasis. In the African region, four countries (Burundi, Rwanda, Togo and Mauritius) and seven countries (Burkina Faso, Ghana, Mali, Namibia, Niger, the Seychelles and Zimbabwe) are preparing elimination dossiers for schistosomiasis and STH respectively. These are supported by the Expanded Special Project for the Elimination of Neglected Tropical Diseases (ESPEN), which organised a workshop on 19–21 May 2026 to help the above countries prepare high-quality, WHO-compliant elimination dossiers. It is expected that these will be finalised and submitted in 2027.

In December 2025, the regional office of the Americas organised an expert meeting to review the status of schistosomiasis transmission and set a plan for preparing the schistosomiasis elimination dossier for submission. A dossier review will be undertaken to remove Saint Martin and Montserrat from the list of endemic countries and territories, and the region will provide support for the preparation of elimination dossiers for other countries.

Algeria, Indonesia, Egypt and Iran (Islamic Republic of) have submitted dossiers to be recognised as having eliminated schistosomiasis as a public health problem and interrupted its transmission (in the case of Iran [Islamic Republic of]). These are currently under review.

Schistosomiasis and STH 2026 global programme review meeting

WHO organized a review meeting on schistosomiasis and STH programmes on 25–27 March 2026 in Addis Ababa, Ethiopia, to review progress and discuss challenges towards achieving the WHO 2030 NTD road map targets for schistosomiasis and STH. Participants at the meeting, which included national programme managers, WHO regional focal points and partners, recommended the following urgent actions:

  • Acceleration and increase of treatment coverage to optimize the use of donated drug to reduce the prevalence and intensity of schistosomiasis and STH before 2030. This will enable endemic countries to reduce the population in need of treatment and the number of tablets needed after 2030 given the uncertainty around future medicine donations for STH.
  • Implementation of impact assessment surveys as their results are essential to allowing programmes to modify resource allocation and treatment frequency as disease epidemiology changes. The objective is to ensure that treatment is delivered effectively where it remains needed.
  • Integration of schistosomiasis and STH deworming into national health systems to ensure sustainable delivery as donor support declines.
  • Adaptation and development of strategies that will ensure continuity of care for people and communities in need of treatment, for the sustainability of schistosomiasis and STH programmes with the decline of external funding.
  • Institutionalization of PC within national health systems, strengthening domestic ownership and financing, improvement of community engagement and behaviour change; and the scaling up of WASH and One Health approaches were suggested as strategies for sustainability.

Discussion

The number of people who were reported to require PC for schistosomiasis globally in 2025 was 236.1 million (Figure 2). This represents a reduction of 17.6 million people (67% adults and 33% SAC) requiring PC for schistosomiasis compared to 2024, due mainly to lower administrative level estimation of the target by programmes. Globally, 77.4 million people received treatment for schistosomiasis in 2025, for a coverage of 32.8%. Compared to 2024, there is a reduction of 23 million of the number of treatments, corresponding to 22.9%. This reduction concerns mostly SAC (78%). Despite a higher number of countries who implemented PC for schistosomiasis in 2025, there was a reduction of the number of IUs targeted for treatment due the lack of funding. The majority of the treatment has been provided in the African region (95.9%). Globally, 12 countries requiring PC for schistosomiasis have not conducted MDA in 2025 (10 in the African, one in the Americas, and one in the Eastern Mediterranean regions); among them Mozambique, Zambia and Sudan, which have substantial numbers of people requiring PC. Global coverage of treatment for adults remains low (11.5%) even though 70.3% of countries are reporting implementing adult treatment during PC (25 of the 38 countries reporting). In line with WHO schistosomiasis elimination guidelines, treatment of pre-SAC has been conducted by two countries who reported the treatment of 466 488 pre-SAC using the current praziquantel formulation.

Number of people requiring and receiving preventive chemotherapy for schistosomiasis and global coverage (%), 2017–2025
Figure 2. Number of people requiring and receiving preventive chemotherapy for schistosomiasis and global coverage (%), 2017–2025
SAC, school-aged children.
CloseNumber of people requiring and receiving preventive chemotherapy for schistosomiasis and global coverage (%), 2017–2025
Figure 2. Number of people requiring and receiving preventive chemotherapy for schistosomiasis and global coverage (%), 2017–2025
SAC, school-aged children.

Globally, in 2025 the population in need of PC for STH was reduced by 25.6 million compared to 2024 (Figure 3). The number of pre-SAC and SAC reported as treated for STH also declined from 507 million in 2024 to 396.1 million in 2025. Consequently, the global treatment coverage decreased from 57.5% to 46.2%. The largest regional declines were observed in the South-East Asia and African regions. In South-East Asia, this could be explained by the fact that in 2025, no PC was conducted in Bangladesh and the Democratic People’s Republic of Korea did not report treatment data; and there was a reduction of treatments in India, with a decline of the proportion of number of children treated from 64.4% in 2024 to 54.0% in 2025. In the African region, treatment coverage decreased from 49.6% in 2024 to 39.1% in 2025. This reduction was driven mainly by the decline in the reported proportion of children dewormed in Nigeria from 43.5% to 26.2%. Changes in this country’s pharmaceutical regulatory and procurement environment contributed to constraints in the availability of albendazole and mebendazole for planned PC activities. Consequently, the number of children who could be reached was reduced. This situation highlights the broader risk of transition for large-scale PC programmes.

Number of people requiring and receiving preventive chemotherapy for soil-transmitted helminthiases (STH) and global coverage (%), 2017–2025
Figure 3. Number of people requiring and receiving preventive chemotherapy for soil-transmitted helminthiases (STH) and global coverage (%), 2017–2025
PRE_SAC, preschool-aged children; SAC, school-aged children.
CloseNumber of people requiring and receiving preventive chemotherapy for soil-transmitted helminthiases (STH) and global coverage (%), 2017–2025
Figure 3. Number of people requiring and receiving preventive chemotherapy for soil-transmitted helminthiases (STH) and global coverage (%), 2017–2025
PRE_SAC, preschool-aged children; SAC, school-aged children.

Where domestic resources or procurement systems are insufficient to meet programme requirements, pragmatic transitional arrangements are necessary to avoid programme delivery disruptions. These arrangements should include continued access to drug donations and other procurement options. Ensuring the continuity of the supply of medicines during such transitions is essential in order to protect previous gains and maintain progress towards eliminating soil-transmitted helminthiasis and other neglected tropical diseases as public health problems. Progress towards greater national ownership and self-reliance requires sustainable financing and procurement mechanisms to ensure continued access to quality-assured medicines.

Conclusion

Globally, compared to 2024, there is a reduction of the number of people receiving PC for schistosomiasis (-22.9%) and STH (-22%) in 2025 as a consequence of the global reduction of development aid. New strategies such as integration of PC with other public health interventions is essential to ensure that PC is provided to people in need in all endemic areas of countries.

References
  1. Global Health Estimates 2023: Disease burden by Cause, Age, Sex, by Country and by Region, 2000–2023. Geneva, World Health Organization; 2026 ↩︎

  2. Chen J, Gong Y, Chen Q, Li S, Zhou Y. Global burden of soil-transmitted helminth infections, 1990–2021. Infect Dis Poverty. 2024;13:77. https://doi.org/10.1186/s40249-024-01238-9 ↩︎

  3. Maia da Costa V et al. Urinary schistosomiasis outbreak in Cabo Verde: the first description in the country, May–June, 2022. PAMJ One Health. 2024;13:13. https://doi.org/10.11604/pamj-oh.2024.13.13.41435 ↩︎

  4. Preventive chemotherapy data portal. Geneva: World Health Organization; 2018 (https://www.who.int/data/preventive-chemotherapy, accessed October 2026). ↩︎

  5. Soil-transmitted helminthiases: estimates of the number of children needing preventive chemotherapy and number treated, 2009. Wkly Epidemiol Rec. 2011;86(25):257–266. ↩︎

Show lessShow more

To the top ↑